ALTUVIIIO, also known as efanesoctocog alfa, is an antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein used for perioperative management of bleeding, controlling bleeding episodes, and routine prophylaxis. The recommended
This acquisition aligns with Lupin’s strategic goal to strengthen its position in the key therapeutic portfolio in India. The brands agreed to be acquired consists of Piclin (Picosulphate
The company submitted the application in August this year seeking approval for the initiation of Phase I clinical trial of KB408. The regulator, after the 30-day review of
With an area of around 7,000m2, the new location features the XBCM2 dual-function facility for bioconjugate drug substance and antibody intermediates production. It also comprises the XDP2 facility,
Cabotegravir is indicated for use in high-risk adults and adolescents aged a minimum of 12 years weighing at least 35 kg. It is claimed to be the first
KT-333 is a highly selective degrader of STAT3, a transcriptional regulator that is linked to inflammatory and autoimmune diseases as well as various cancers. The company is also
A Final Draft Guidance (FDG) has been issued for QUVIVIQ for the treatment of these patients with symptoms lasting for three nights or more per week for at
Through the collaboration, BeiGene can access Nona’s fully human transgenic mice platform, Harbour Mice. In 2018, BeiGene received the rights to leverage the Harbour Mice heavy chain (H2L2)
Under the agreement, Synaffix will be eligible for an upfront payment, milestone payments along with tiered royalties on net sales of resulting products. The company will also produce
Under the partnership, the companies will reveal the drug candidate’s mechanism of action as well as pharmacological characterisation. Salipro Biotech CEO Jens Frauenfeld said: “We are excited to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.